CLL Support Association
9,296 members14,675 posts

Another humanized monoclonal antibody RG7356, in development by Roche

Another humanized monoclonal antibody RG7356, in development by Roche

Roche are developing RG7356, which targets CD44, a surface receptor that is over-expressed in ZAP-70 positive CLL patients as well as some solid tumours. If early phase clinical trials proceed and show promise, this could be good news for ZAP-70 positive patients, given the generally poorer prognosis associated with this marker.

The full paper is available from the on-line edition of the Proceedings of the National Academy of Sciences:

pnas.org/content/110/15/612...

Neil

You may also like...